Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Core Insights - Solid Biosciences Inc. is advancing its gene therapy programs for neuromuscular and cardiac diseases, with significant clinical milestones expected in 2025 and beyond [3][5][6] Financial Overview - As of December 31, 2024, the company reported $148.9 million in cash, cash equivalents, and available-for-sale securities, an increase from $123.6 million in 2023 [2][18] - The company anticipates a cash runway into the first half of 2027, bolstered by $200 million in gross proceeds from a recent equity offering [2][18] Clinical Development Updates - Initial data from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 showed promising safety and improvements in muscle integrity biomarkers, with plans for FDA discussions on accelerated approval pathways in mid-2025 [3][7][8] - SGT-212, targeting Friedreich's ataxia, received FDA IND clearance, with the first human trial expected to start in the second half of 2025 [5][7][10] Pipeline and Partnerships - The proprietary capsid AAV-SLB101 used in SGT-003 demonstrated robust transduction and expression levels, leading to potential partnerships with 19 academic and corporate entities [4][13] - The company is building a library of capsids and promoters for future gene therapy applications, with a focus on cardiac and neuromuscular diseases [12][13] Research and Development Expenses - R&D expenses for Q4 2024 were $30.8 million, up from $15.5 million in Q4 2023, with full-year R&D expenses totaling $96.4 million compared to $76.6 million in 2023 [18][21] - General and administrative expenses also increased, reflecting higher personnel costs, totaling $33.3 million for the full year 2024 [18][21] Net Loss - The net loss for Q4 2024 was $42.6 million, compared to $20.3 million in Q4 2023, with a full-year net loss of $124.7 million versus $96.0 million in 2023 [18][21]